Narissa Kreyer predicts Alterna will demonstrate AP-003 establishes functional protein and impacts biomarkers/efficacy endpoints in humans within five years
“in five years, I really hope that we have shown in humans that AP-three is able to establish functional protein and have that impact on biomarkers and efficacy endpoints”
→ Read the source episode
Our resolution criterion
disputablePublished clinical trial data showing AP-003 demonstrates functional protein restoration and measurable impact on biomarkers or efficacy endpoints in human subjects
More from Beyond Biotech
Stuart Medina predicts Bio Spain 2026 Talent Day will exceed the 125 job interviews arranged in the previous year
Per London predicts EVOX will generate initial clinical data from Huntington's trials in 2028-2029.
Per London expresses hope that EVOX's Huntington's therapy will be routinely used clinically within 10 years (by 2036).
Per Lundin predicts EVOX's Huntington's gene editing therapy will be in routine clinical use within 10 years from 2026.
Laurent Levy predicts Nanobiotics will complete pancreatic, melanoma, and esophageal cancer trials before H1 2027
Narissa Kreyer predicts Alterna will conduct a clinical study in adult PKU patients demonstrating AP-003 protein generation and biomarker reduction
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.